Peak Processing Team at Canadian facility. Source: Althea
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Australian pharmaceutical company Althea Group Holdings (AGH) Canadian subsidiary, Peak Processing Solutions, has received its cannabis licence and will commence operations
  • The company will now manufacture cannabis- infused beverages, concentrates and tropicals at its facility in Tecumseh, Ontario
  • Peak Processing Solutions is aiming to achieve C$25 million (around A$26 million) revenue within 18 months
  • Additionally, Peak signed with a second beverage company, Blum Beverages, which is a Canadian non-alcoholic beverage company
  • On the market this afternoon, Althea is up 9.48 per cent and is trading for 63.5 cents per share

Althea Group Holdings (AGH) Canadian subsidiary, Peak Processing Solutions, has commenced operations after receiving its cannabis licence.

Peak has received its Standard Processing Licence from Health Canada and will immediately commence commercial operations.

The company will now manufacture cannabis-infused beverages, concentrates and tropicals (Cannabis 2.0 products) at its facility in Tecumseh, Ontario. The facility is one of the first large-scale independent processing facilities of its kind.

Peak will manufacture Cannabis 2.0 products on behalf of third parties as well as supply medicinal products to Althea. The company is also aiming to achieve C$25 million (around A$26 million) revenue within 18 months.

Research has estimated that the Cannabis 2.0 market is currently worth C$2.7 billion (around A$2.8 billion) annually, with cannabis extract-based products accounting for C$1.6 billion (approx A$1.5 billion).

Processing facility. Sourced: Althea.

The Blum Beverage Agreement

In addition to the licence, Peak has also signed an agreement with Blum Beverages, a Canadian non-alcoholic beverage company.

Under the agreement, Blum will be able to place orders for Peak to manufacture and distribute cannabis beverages. The beverages will have 5 milligrams of tetrahydrocannabinol (THC).

The commercial terms for this agreement remain confidential.

Althea CEO, Josh Fegan, is pleased with the cannabis licence.

“This is a major milestone and will allow Peak to immediately commence production of cannabis-infused canned beverages for Collective Project and Blum, sign further customers who were waiting for the licence to be granted, and start supplying our own pharmaceutical operations with finished (Althea) products at a drastically lower cost than we currently pay to third party suppliers,” he said.

“We are excited by the potential to serve the burgeoning Cannabis 2.0 market and look forward to providing updates on our progress,” he added.

On the market this afternoon, Althea is up 9.48 per cent and is trading for 63.5 cents per share at 12:19 pm AEST.

agh by the numbers
More From The Market Online

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…

TruScreen continues global growth with product registration in Kenya

TruScreen Group has received product registration in the Republic of Kenya, a priority market for cervical…